<p>根據 MarketBeat.com 的報道，Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）的股票獲得了目前覆蓋該公司的 19 家評級公司的平均評級為 “適度買入”。兩名股票研究分析師對該股票給予了持有評級，十七名分析師對該公司發佈了買入評級。在過去一年中，覆蓋該股票的經紀公司平均 12 個月的目標價為 1,017.67 美元。</p>
<p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<ul>
<li>目前哪個醫療保健股票是最佳買入？</li>
</ul>
<p>最近，一些股票分析師對 LLY 股票發表了看法。Berenberg Bank 在 1 月 16 日的研究報告中將 Eli Lilly and Company 的股票目標價設定為 970.00 美元。摩根士丹利在週三將 Eli Lilly and Company 的目標價從 1,146.00 美元下調至 1,124.00 美元，並對該公司給予了 “增持” 評級。Truist Financial 在 2 月 3 日的報告中將 Eli Lilly and Company 的目標價從 1,029.00 美元提高至 1,038.00 美元，並給予該股票 “買入” 評級。富國銀行在 3 月 5 日的研究報告中將 Eli Lilly and Company 的目標價從 970.00 美元提高至 1,100.00 美元，並給予該股票 “增持” 評級。最後，高盛集團在週二將 Eli Lilly and Company 的股票評級從 “中性” 上調至 “買入”，並將該公司的目標價從 892.00 美元下調至 888.00 美元。</p>
<p><strong>查看我們對 Eli Lilly and Company 的最新分析</strong></p>
<h2>內部人士下注</h2>
<ul>
<li>目標價顯示這 3 只股票接近 1 萬億美元的標誌</li>
</ul>
<p>在其他新聞中，首席會計官 Donald A. Zakrowski 在 3 月 13 日的交易中出售了 1,000 股公司的股票。該股票以 818.24 美元的平均價格出售，總交易額為 818,240.00 美元。出售後，首席會計官現在直接持有該公司 5,840 股股票，價值約為 4,778,521.60 美元。此次交易使其持股減少了 14.62%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。公司內部人士持有公司股票的 0.13%。</p>
<h2>機構投資者對 Eli Lilly and Company 的看法</h2>
<p>幾家機構投資者和對沖基金最近買賣了該公司的股票。GAMMA Investing LLC 在第一季度將其在 Eli Lilly and Company 的持倉提高了 103,831.6%。GAMMA Investing LLC 現在擁有 14,866,380 股該公司的股票，價值為 12,278,292,000 美元，此前在上一季度購買了額外的 14,852,076 股。挪威銀行在第四季度獲得了 Eli Lilly and Company 的新頭寸，價值約為 8,407,908,000 美元。Proficio Capital Partners LLC 在第四季度將其在 Eli Lilly and Company 的持倉提高了 100,387.1%。Proficio Capital Partners LLC 現在擁有 5,202,215 股該公司的股票，價值為 4,016,110,000 美元，此前在該期間購買了額外的 5,197,038 股。Wellington Management Group LLP 在第四季度將其在 Eli Lilly and Company 的股份提高了 19.0%。Wellington Management Group LLP 現在擁有 12,625,925 股該公司的股票，價值為 9,747,214,000 美元，此前在上一季度購買了額外的 2,012,129 股。最後，Capital International Investors 在第四季度將其在 Eli Lilly and Company 的持倉提高了 23.2%。Capital International Investors 現在擁有 8,730,758 股該公司的股票，價值為 6,740,272,000 美元，此前在該期間獲得了額外的 1,645,222 股。機構投資者持有公司 82.53% 的股票。</p>
<h2>Eli Lilly and Company 股票下跌 4.5%</h2>
<ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
<p>Eli Lilly and Company 的股票在週五開盤價為 719.85 美元。Eli Lilly and Company 的 1 年最低價為 677.09 美元，1 年最高價為 972.53 美元。該公司的市值為 6825.4 億美元，市盈率為 61.47，市盈增長比率為 1.40，貝塔值為 0.51。該公司的流動比率為 1.15，速動比率為 0.97，債務與股本比率為 2.00。該股票的 50 日移動平均價格為 838.96 美元，200 日移動平均價格為 824.81 美元。</p>
<p>Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）最近在 2 月 6 日發佈了季度財報。該公司報告每股收益（EPS）為 5.32 美元，低於分析師一致預期的 5.45 美元，差額為 0.13 美元。Eli Lilly and Company 的股本回報率為 85.24%，淨利潤率為 23.51%。整體來看，分析師預計 Eli Lilly and Company 在當前財政年度將發佈 23.48 美元的每股收益。</p>
<h2>Eli Lilly and Company 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更喜歡的五隻股票比 Eli Lilly and Company 更好</li>
<li>交易暫停解釋</li>
<li>Joby Aviation：運營勢頭與市場情緒的對比</li>
<li>3 只 REITs 值得長期買入和持有</li>
<li>博通的強勁表現顯示出關税下降中的韌性</li>
<li>Roth IRA 計算器：計算您的潛在回報</li>
<li>Carvana：能否通過強勁的轉機超越市場逆風？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>禮來公司（NYSE: LLY）獲得了 19 家券商的 “適度買入” 平均評級。分析師設定的 12 個月價格目標平均為 1,017.67 美元，其中包括兩項持有評級和十七項買入評級。最近的價格目標包括來自貝倫貝格銀行的 970.00 美元和來自富國銀行的 1,100.00 美元。該股票開盤價為 719.85 美元，1 年最低價為 677.09 美元，最高價為 972.53 美元。機構投資者持有該公司 82.53% 的股份，禮來在上個季度報告的每股收益為 5.32 美元，低於預期 0.13 美元</p>

<p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) have received an average rating of &#34;Moderate Buy&#34; from the nineteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $1,017.67.</p>
<div class="lb-trans"><p>根據 MarketBeat.com 的報道，Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）的股票獲得了目前覆蓋該公司的 19 家評級公司的平均評級為 “適度買入”。兩名股票研究分析師對該股票給予了持有評級，十七名分析師對該公司發佈了買入評級。在過去一年中，覆蓋該股票的經紀公司平均 12 個月的目標價為 1,017.67 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪個醫療保健股票是最佳買入？</li>
</ul>
</div><p>A number of equities analysts have recently weighed in on LLY shares. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, February 3rd. Wells Fargo &amp; Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and cut their price target for the company from $892.00 to $888.00 in a report on Tuesday.</p>
<div class="lb-trans"><p>最近，一些股票分析師對 LLY 股票發表了看法。Berenberg Bank 在 1 月 16 日的研究報告中將 Eli Lilly and Company 的股票目標價設定為 970.00 美元。摩根士丹利在週三將 Eli Lilly and Company 的目標價從 1,146.00 美元下調至 1,124.00 美元，並對該公司給予了 “增持” 評級。Truist Financial 在 2 月 3 日的報告中將 Eli Lilly and Company 的目標價從 1,029.00 美元提高至 1,038.00 美元，並給予該股票 “買入” 評級。富國銀行在 3 月 5 日的研究報告中將 Eli Lilly and Company 的目標價從 970.00 美元提高至 1,100.00 美元，並給予該股票 “增持” 評級。最後，高盛集團在週二將 Eli Lilly and Company 的股票評級從 “中性” 上調至 “買入”，並將該公司的目標價從 892.00 美元下調至 888.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Eli Lilly and Company 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li>
</ul>
<div class="lb-trans"><ul>
<li>目標價顯示這 3 只股票接近 1 萬億美元的標誌</li>
</ul>
</div><p>In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.13% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席會計官 Donald A. Zakrowski 在 3 月 13 日的交易中出售了 1,000 股公司的股票。該股票以 818.24 美元的平均價格出售，總交易額為 818,240.00 美元。出售後，首席會計官現在直接持有該公司 5,840 股股票，價值約為 4,778,521.60 美元。此次交易使其持股減少了 14.62%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。公司內部人士持有公司股票的 0.13%。</p>
</div><h2>Institutional Investors Weigh In On Eli Lilly and Company</h2>
<div class="lb-trans"><h2>機構投資者對 Eli Lilly and Company 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $8,407,908,000. Proficio Capital Partners LLC lifted its position in shares of Eli Lilly and Company by 100,387.1% during the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after buying an additional 5,197,038 shares during the period. Wellington Management Group LLP boosted its stake in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares in the last quarter. Finally, Capital International Investors grew its position in Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after acquiring an additional 1,645,222 shares during the period. Institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買賣了該公司的股票。GAMMA Investing LLC 在第一季度將其在 Eli Lilly and Company 的持倉提高了 103,831.6%。GAMMA Investing LLC 現在擁有 14,866,380 股該公司的股票，價值為 12,278,292,000 美元，此前在上一季度購買了額外的 14,852,076 股。挪威銀行在第四季度獲得了 Eli Lilly and Company 的新頭寸，價值約為 8,407,908,000 美元。Proficio Capital Partners LLC 在第四季度將其在 Eli Lilly and Company 的持倉提高了 100,387.1%。Proficio Capital Partners LLC 現在擁有 5,202,215 股該公司的股票，價值為 4,016,110,000 美元，此前在該期間購買了額外的 5,197,038 股。Wellington Management Group LLP 在第四季度將其在 Eli Lilly and Company 的股份提高了 19.0%。Wellington Management Group LLP 現在擁有 12,625,925 股該公司的股票，價值為 9,747,214,000 美元，此前在上一季度購買了額外的 2,012,129 股。最後，Capital International Investors 在第四季度將其在 Eli Lilly and Company 的持倉提高了 23.2%。Capital International Investors 現在擁有 8,730,758 股該公司的股票，價值為 6,740,272,000 美元，此前在該期間獲得了額外的 1,645,222 股。機構投資者持有公司 82.53% 的股票。</p>
</div><h2>Eli Lilly and Company Stock Down 4.5 %</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股票下跌 4.5%</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
</div><p>Shares of Eli Lilly and Company stock opened at $719.85 on Friday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $682.54 billion, a P/E ratio of 61.47, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a 50-day moving average price of $838.96 and a 200 day moving average price of $824.81.</p>
<div class="lb-trans"><p>Eli Lilly and Company 的股票在週五開盤價為 719.85 美元。Eli Lilly and Company 的 1 年最低價為 677.09 美元，1 年最高價為 972.53 美元。該公司的市值為 6825.4 億美元，市盈率為 61.47，市盈增長比率為 1.40，貝塔值為 0.51。該公司的流動比率為 1.15，速動比率為 0.97，債務與股本比率為 2.00。該股票的 50 日移動平均價格為 838.96 美元，200 日移動平均價格為 824.81 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）最近在 2 月 6 日發佈了季度財報。該公司報告每股收益（EPS）為 5.32 美元，低於分析師一致預期的 5.45 美元，差額為 0.13 美元。Eli Lilly and Company 的股本回報率為 85.24%，淨利潤率為 23.51%。整體來看，分析師預計 Eli Lilly and Company 在當前財政年度將發佈 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 公司簡介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Trading Halts Explained</li>
<li>Joby Aviation: Operational Momentum vs. Market Sentiment</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Broadcom's Big Outperformance Shows Strength Amid Tariff Decline</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Carvana: Can Turnaround Strength Outdrive Market Headwinds?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Eli Lilly and Company 更好</li>
<li>交易暫停解釋</li>
<li>Joby Aviation：運營勢頭與市場情緒的對比</li>
<li>3 只 REITs 值得長期買入和持有</li>
<li>博通的強勁表現顯示出關税下降中的韌性</li>
<li>Roth IRA 計算器：計算您的潛在回報</li>
<li>Carvana：能否通過強勁的轉機超越市場逆風？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

禮來公司（NYSE:LLY）獲得券商的 “適度買入” 平均評級